APA (7th ed.) Citation

Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009). The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer. The oncologist (Dayton, Ohio), 14(1), 22-28. https://doi.org/10.1634/theoncologist.2008-0213

Chicago Style (17th ed.) Citation

Hurwitz, Herbert I., Jing Yi, William Ince, William F. Novotny, and Oliver Rosen. "The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio) 14, no. 1 (2009): 22-28. https://doi.org/10.1634/theoncologist.2008-0213.

MLA (9th ed.) Citation

Hurwitz, Herbert I., et al. "The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio), vol. 14, no. 1, 2009, pp. 22-28, https://doi.org/10.1634/theoncologist.2008-0213.